Efficacy of Cantharidin in Molluscum Contagiosum
|ClinicalTrials.gov Identifier: NCT00667225|
Recruitment Status : Completed
First Posted : April 28, 2008
Results First Posted : June 1, 2011
Last Update Posted : June 21, 2011
|Condition or disease||Intervention/treatment|
|Molluscum Contagiosum, Skin Disease||Drug: cantharidin's vehicle Drug: Cantharidin 0.7%|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy of Cantharidin in Molluscum Contagiosum: A Randomized, Blinded, Placebo-Controlled Prospective Study|
|Study Start Date :||January 2008|
|Primary Completion Date :||June 2009|
|Study Completion Date :||June 2009|
Placebo Comparator: I
Subjects in this group will have topical application of cantharidin's vehicle at each visit.
Drug: cantharidin's vehicle
Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
Subjects in this group will have topical application of cantharidin at each visit.
Drug: Cantharidin 0.7%
Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
- Patients Experiencing Complete Clearance of All Molluscum Lesions. [ Time Frame: Baseline compared to 8 weeks (5 visits) ]
- Mean Change in Each Group Measured by Lesion Count. [ Time Frame: Baseline compared to 8 weeks (5 visits) ]Average change in number of lesions from baseline to 8 weeks
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00667225
|United States, North Carolina|
|University of North Carolina|
|Chapel Hill, North Carolina, United States, 27514|
|Principal Investigator:||Jacquelyn R Dosal, MD||UNC|